Eye drop showdown: which works best for dry eye during cataract surgery?

NCT ID NCT07397949

Not yet recruiting Symptom relief Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two common eye drops—rebamipide and diquafosol—for managing dry eye in people having cataract surgery. Sixty adults with mild to moderate dry eye will use one of the drops four times a day, starting one month before surgery and continuing for three months after. Researchers will check tear film stability and dry eye symptoms to see if one treatment is as good as the other.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rebamipide 2% ophthalmic solution and Diquafosol 3% ophthalmic solution
What this could lead to: If one eye drop is shown to be as effective as the other, doctors may have more options to manage dry eye around cataract surgery, improving comfort and vision outcomes.
What could go wrong: This is a small, early-stage trial with only 60 participants, so results may not apply to everyone. There is also a chance neither treatment proves clearly better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATARACT DRY EYE DISEASE (DED)

Contacts and locations

Locations

Samsung Mec

Seoul, Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.